A Comprehensive Assessment of Hepatobiliary Disorders in HIV-Infected Patients Treated with Dolutegravir, Elvitegravir, Raltegravir or Darunavir in the OPERA Database

Michael Wohlfeiler, Karam Monzur, Laurence Brunet, Jennifer Fusco, Vani Vannappagari, Lloyd Curtis, Nassim Payandi, Michael Aboud, Richy Hsu, Philip Lackey, and Gregory Fusco


BACKGROUND

- Higher levels of liver enzyme elevation (≥5x ULN) were reported for ritonavir-boosted darunavir (RAL) vs. dolutegravir (DTG) in this study.
- RAL users were less likely than DTG users to have a history of advanced liver fibrosis (Figure 3) and experienced patients; RAL users were less likely to be naïve (17% vs. 24.5%; p = 0.0003).

RESULTS

- Screening for hepatobiliary disorders was not performed at baseline or in the 12-month period preceding study end.
- Participants prescribed EVG were less likely to have elevated liver chemistries at baseline compared to participants prescribed DTG (Figure 2).
- Patients prescribed EVG were less likely to have elevation in liver chemistries at baseline compared to patients prescribed DTG (Figure 2).

DISCUSSION

- RAL users were more likely than DTG users to have a history of advanced liver fibrosis and advanced liver fibrosis with significant inflammation (Figure 3) and experienced patients; RAL users were less likely to be naïve (17% vs. 24.5%; p = 0.0003).
- Patients prescribed EVG were less likely to have elevation in liver chemistries at baseline compared to patients prescribed DTG (Figure 2).

METHODS

- Operative HIV caregivers and their patients. Additionally, we are grateful to the OPERA HIV caregivers and their patients. This research was funded by ViiV Healthcare.

ACKNOWLEDGMENTS

- This research would not be possible without the generosity of the OPERA HIV caregivers and their patients. Additionally, we are grateful to the OPERA caregivers and their patients for sharing their stories and personal experiences with us.

SPONSORSHIP

- This research was supported by the research fund of ViiV Healthcare.

Contact Information: Laurence Brunet

600 Imperial Blvd, Suite 1230, Durham, NC 27703

Phone: 919-260-2500  Fax: 919-260-2322  Email: laurence.brunet@viiiv.com

Presented at the 22nd International AIDS Conference ~ Amsterdam, the Netherlands

#AIDS2018 | @AIDSConference | www.aids2018.org